Literature DB >> 12910687

[Protective effect of berberine on cardiac myocyte injured by ischemia-reperfusion].

Lingyun Zheng1, Zuyu Zhou, Dachang Tao, Tingjian Lan.   

Abstract

OBJECTIVE: To observe the protective effect of berberine on cardiac myocyte injured by ischemia-reperfusion(I/R) in neonatal rats.
METHODS: Cardiac myocytes from neonatal SD rat were cultured and pretreated with berberine in three different concentrations, 1.5 x 10(-6) mol/L, 1.5 x 10(-5) mol/L and 1.5 x 10(-4) mol/L, before exposure to hypoxia (95% N2-5% CO2) for 24 h and reoxygenation (95% air-5% CO2) for 1 h to create cell model of ischemia-reperfusion. Then lactate dehydrogenase (LDH) release, methylenedioxyamphetamine (MDA) release superoxide dismutase (SOD) activity were measured, and cell apoptosis was detected.
RESULTS: Compared with the measurements taken in normal group, the LDH and MDA in the supernatant of the cells in ischemia and reperfusion group increased highly (P < 0.01), SOD activity decreased sharply (P < 0.01), and apoptosis of cells in ischemia groups and reperfusion groups increased highly (P < 0.01). Pretreatment of myocytes with berberine resulted in reduction in LDH and MDA release (P < 0.01) in I/R groups, attenuation of apoptosis in ischemia and reperfusion groups (P < 0.01). When the concentration of berberine was increased, these effects were getting obvious. Especially when the myocytes were pretreated with berberine at 1.5 x 10(-5) mmol/L, the cell apoptosis rates were 14.4% and 20% in ischemia group and reperfusion group, which were lower than the rates of 17.4% and 41% before pretreatment, respectively.
CONCLUSION: Berberine alleviates I/R injury and attenuates apoptosis in myocytes exposed to I/R. These effects partly depend on the concentration of berberine.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12910687

Source DB:  PubMed          Journal:  Sichuan Da Xue Xue Bao Yi Xue Ban        ISSN: 1672-173X


  7 in total

1.  Berberine inhibits norepinephrine-induced apoptosis in neonatal rat cardiomyocytes via inhibiting ROS-TNF-α-caspase signaling pathway.

Authors:  Xiu-xiu Lv; Xiao-hui Yu; Hua-dong Wang; Yu-xia Yan; Yan-ping Wang; Da-Xiang Lu; Ren-Bin Qi; Chao-Feng Hu; Hong-Mei Li
Journal:  Chin J Integr Med       Date:  2012-02-29       Impact factor: 1.978

2.  The protective effect of berberine on β-cell lipoapoptosis.

Authors:  N Gao; T-Y Zhao; X-J Li
Journal:  J Endocrinol Invest       Date:  2010-04-22       Impact factor: 4.256

3.  Berberine improves glucose metabolism through induction of glycolysis.

Authors:  Jun Yin; Zhanguo Gao; Dong Liu; Zhijun Liu; Jianping Ye
Journal:  Am J Physiol Endocrinol Metab       Date:  2007-10-30       Impact factor: 4.310

4.  San-Huang-Xie-Xin-Tang Prevents Rat Hearts from Ischemia/Reperfusion-Induced Apoptosis through eNOS and MAPK Pathways.

Authors:  Shu-Fen Liou; Hung-Jen Ke; Jong-Hau Hsu; Jyh-Chong Liang; Hung-Hong Lin; Ing-Jun Chen; Jwu-Lai Yeh
Journal:  Evid Based Complement Alternat Med       Date:  2011-04-14       Impact factor: 2.629

5.  N-n-Butyl Haloperidol Iodide, a Derivative of the Anti-psychotic Haloperidol, Antagonizes Hypoxia/Reoxygenation Injury by Inhibiting an Egr-1/ROS Positive Feedback Loop in H9c2 Cells.

Authors:  Ting Sun; Yanmei Zhang; Shuping Zhong; Fenfei Gao; Yicun Chen; Bin Wang; Wenfeng Cai; Zhaojing Zhang; Weiqiu Li; Shishi Lu; Fuchun Zheng; Ganggang Shi
Journal:  Front Pharmacol       Date:  2018-01-25       Impact factor: 5.810

6.  Berberine attenuates convulsing behavior and extracellular glutamate and aspartate changes in 4-aminopyridine treated rats.

Authors:  Hamid Reza Sadeghnia; Ali Reza Taji; Fatemeh Forouzanfar; Hossein Hosseinzadeh
Journal:  Iran J Basic Med Sci       Date:  2017-05       Impact factor: 2.699

Review 7.  Berberine in Cardiovascular and Metabolic Diseases: From Mechanisms to Therapeutics.

Authors:  Xiaojun Feng; Antoni Sureda; Samineh Jafari; Zahra Memariani; Devesh Tewari; Giuseppe Annunziata; Luigi Barrea; Sherif T S Hassan; Karel Šmejkal; Milan Malaník; Alice Sychrová; Davide Barreca; Lovro Ziberna; Mohamad Fawzi Mahomoodally; Gokhan Zengin; Suowen Xu; Seyed Mohammad Nabavi; Ai-Zong Shen
Journal:  Theranostics       Date:  2019-03-16       Impact factor: 11.556

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.